• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    EVP, CHIEF SCIENTIFIC OFFICER Zinda Michael sold $6,397 worth of shares (5,611 units at $1.14), decreasing direct ownership by 7% to 80,297 units (SEC Form 4)

    3/14/25 4:30:19 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Zinda Michael

    (Last) (First) (Middle)
    C/O REPARE THERAPEUTICS INC.

    (Street)
    ST-LAURENT A8 H4S 1Z9

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Repare Therapeutics Inc. [ RPTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP, CHIEF SCIENTIFIC OFFICER
    3. Date of Earliest Transaction (Month/Day/Year)
    03/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Shares 03/12/2025 S(1) 5,611 D $1.14 80,297 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represent shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the vesting and settlement of restricted stock units and does not represent a discretionary sale by the holder.
    /s/ Steve Forte, Attorney-in-Fact 03/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RPTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RPTX

    DatePrice TargetRatingAnalyst
    6/9/2023$11.00 → $16.00Hold → Buy
    Stifel
    2/3/2023$28.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2023$28.00Overweight
    CapitalOne
    4/12/2022$11.00Buy → Hold
    Stifel
    3/17/2022$43.00Buy
    Goldman
    9/23/2021$48.00Buy
    Stifel
    9/13/2021$54.00Buy
    HC Wainwright & Co.
    8/16/2021$45.00 → $47.00Overweight
    Morgan Stanley
    More analyst ratings

    $RPTX
    SEC Filings

    See more
    • SEC Form 8-K filed by Repare Therapeutics Inc.

      8-K - Repare Therapeutics Inc. (0001808158) (Filer)

      6/20/25 4:05:25 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Repare Therapeutics Inc.

      8-K - Repare Therapeutics Inc. (0001808158) (Filer)

      6/17/25 4:05:34 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Repare Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K/A - Repare Therapeutics Inc. (0001808158) (Filer)

      6/2/25 4:13:02 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

      Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

      Repare Therapeutics Inc. ("Repare") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ("DCx"), a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures. Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment. "We have taken careful steps to evaluate all aspects of our business to ensure continued value generation,

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Mini-Oral Presentation Details: Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center Session: Innovative Ap

      4/25/25 1:00:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bvf Partners L P/Il bought $6,249,889 worth of shares (1,227,301 units at $5.09) (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      11/17/23 4:54:43 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bvf Partners L P/Il bought $2,821,352 worth of shares (783,709 units at $3.60) (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      11/3/23 5:37:44 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Repare Therapeutics upgraded by Stifel with a new price target

      Stifel upgraded Repare Therapeutics from Hold to Buy and set a new price target of $16.00 from $11.00 previously

      6/9/23 7:34:45 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Repare Therapeutics from Overweight to Equal-Weight and set a new price target of $15.00 from $28.00 previously

      2/3/23 7:35:18 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Repare Therapeutics with a new price target

      CapitalOne initiated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $28.00

      1/6/23 8:30:21 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Finance and CAO Alves Sandra Isabelle Barros was granted 4,100 shares, increasing direct ownership by 16% to 29,622 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/29/25 5:07:34 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Alves Sandra Isabelle Barros claimed ownership of 25,522 shares (SEC Form 3)

      3 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/29/25 5:05:52 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, CHIEF FINANCIAL OFFICER Forte Steve

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/4/25 4:15:09 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care